Production (Stage)
Microbix Biosystems Inc.
MBX.TO
TSX
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -7.44% | 1.28% | 52.31% | 39.03% | 44.64% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -7.44% | 1.28% | 52.31% | 39.03% | 44.64% |
| Cost of Revenue | -14.33% | 0.54% | 9.63% | 16.11% | 40.40% |
| Gross Profit | -1.64% | 1.88% | 103.92% | 63.19% | 48.41% |
| SG&A Expenses | -9.98% | -11.95% | 13.56% | 9.79% | 28.87% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -10.68% | -4.53% | 10.58% | 12.52% | 32.60% |
| Operating Income | 46.72% | 124.86% | 241.48% | 208.32% | 377.85% |
| Income Before Tax | -58.69% | -45.14% | 15,788.95% | 308.25% | 511.12% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -62.36% | -49.16% | 15,147.09% | 301.63% | 480.29% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -62.36% | -49.16% | 15,147.09% | 301.63% | 480.29% |
| EBIT | 46.72% | 124.86% | 241.48% | 208.32% | 377.85% |
| EBITDA | 35.03% | 76.91% | 405.70% | 433.92% | 470.42% |
| EPS Basic | -62.10% | -49.25% | 19,000.00% | 301.47% | 477.59% |
| Normalized Basic EPS | 72.73% | 228.57% | 216.98% | 175.61% | 200.00% |
| EPS Diluted | -62.50% | -49.49% | 2,462.50% | 287.67% | 408.57% |
| Normalized Diluted EPS | 72.73% | 228.57% | 216.98% | 175.61% | 197.06% |
| Average Basic Shares Outstanding | -0.08% | -0.71% | -0.47% | -0.70% | -0.49% |
| Average Diluted Shares Outstanding | 0.14% | -1.48% | -1.35% | -1.71% | -2.76% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |